Zhejiang Xinguang Pharmaceutical Past Earnings Performance
Past criteria checks 1/6
Zhejiang Xinguang Pharmaceutical's earnings have been declining at an average annual rate of -2.4%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 2.5% per year. Zhejiang Xinguang Pharmaceutical's return on equity is 6.5%, and it has net margins of 20.4%.
Key information
-2.4%
Earnings growth rate
-2.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 2.5% |
| Return on equity | 6.5% |
| Net Margin | 20.4% |
| Last Earnings Update | 31 Mar 2024 |
Revenue & Expenses BreakdownBeta
How Zhejiang Xinguang Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 279 | 57 | 45 | 15 |
| 31 Dec 23 | 270 | 64 | 44 | 15 |
| 30 Sep 23 | 305 | 78 | 48 | 16 |
| 30 Jun 23 | 330 | 87 | 49 | 16 |
| 31 Mar 23 | 342 | 96 | 49 | 15 |
| 31 Dec 22 | 351 | 109 | 51 | 16 |
| 30 Sep 22 | 337 | 116 | 48 | 16 |
| 30 Jun 22 | 332 | 118 | 49 | 14 |
| 31 Mar 22 | 327 | 118 | 49 | 14 |
| 01 Jan 22 | 321 | 114 | 49 | 14 |
| 30 Sep 21 | 317 | 112 | 47 | 13 |
| 30 Jun 21 | 314 | 110 | 49 | 13 |
| 31 Mar 21 | 308 | 111 | 47 | 13 |
| 31 Dec 20 | 283 | 99 | 47 | 12 |
| 30 Sep 20 | 291 | 100 | 49 | 12 |
| 30 Jun 20 | 282 | 97 | 46 | 12 |
| 31 Mar 20 | 277 | 89 | 46 | 14 |
| 31 Dec 19 | 291 | 94 | 46 | 16 |
| 30 Sep 19 | 285 | 91 | 43 | 19 |
| 30 Jun 19 | 283 | 90 | 44 | 19 |
| 31 Mar 19 | 277 | 88 | 43 | 19 |
| 31 Dec 18 | 276 | 88 | 44 | 18 |
| 30 Sep 18 | 292 | 97 | 31 | 29 |
| 30 Jun 18 | 291 | 96 | 36 | 25 |
| 31 Mar 18 | 310 | 106 | 43 | 22 |
| 31 Dec 17 | 311 | 106 | 48 | 18 |
| 30 Sep 17 | 308 | 110 | 66 | 0 |
| 30 Jun 17 | 310 | 113 | 67 | 0 |
| 31 Mar 17 | 306 | 113 | 68 | 0 |
| 31 Dec 16 | 315 | 119 | 68 | 0 |
| 30 Sep 16 | 312 | 117 | 66 | 0 |
| 30 Jun 16 | 312 | 120 | 63 | 0 |
| 31 Mar 16 | 315 | 120 | 64 | 0 |
| 31 Dec 15 | 311 | 119 | 63 | 0 |
| 31 Dec 14 | 292 | 106 | 59 | 0 |
| 31 Dec 13 | 268 | 72 | 57 | 0 |
Quality Earnings: 300519 has high quality earnings.
Growing Profit Margin: 300519's current net profit margins (20.4%) are lower than last year (28.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 300519's earnings have declined by 2.4% per year over the past 5 years.
Accelerating Growth: 300519's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 300519 had negative earnings growth (-41.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-1.5%).
Return on Equity
High ROE: 300519's Return on Equity (6.5%) is considered low.